Ziff Oliver J, Penny Hugo, Frame Sharon, Cronin Antonia, Goldsmith David
Department of Nephrology and Transplantation, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Institute of Cardiovascular Sciences, University College London, London, UK.
Clin Kidney J. 2017 Jun;10(3):411-418. doi: 10.1093/ckj/sfw136. Epub 2017 Jan 7.
Renal transplant recipients (RTRs) are often Vitamin D (VitD) depleted as a result of both chronic kidney disease and mandated sun avoidance behaviours. Repleting VitD may be warranted, but how, and for how long, is unknown, as is the impact of seasonality on the success of repletion. We investigated the impact of seasonality on VitD status following VitD repletion in a large cohort of stable, long-term RTRs. Serum 25-hydroxyvitamin D [25(OH)D] concentrations and bone biochemistry parameters were analysed from 102 VitD repletion courses in 98 RTRs that had undergone VitD repletion. Repletion was delivered over 6 months with either 240 000 IU colecalciferol if pre-repletion serum VitD was between 20 and 50 nmol/L, or with 360 000 IU if VitD was <20 nmol/L. Twelve months post-repletion 25(OH)D and parathyroid hormone (PTH) were available for 75 patients. At baseline, 25(OH)D was 20.1 ± 1.0 nmol/L, increasing to 65.4 ± 1.8 nmol/L following repletion (+7.55 nmol/L/month, P < 0.0001). Twelve months post-repletion and after no further VitD administration, 25(OH)D fell to 35.4 ± 1.8 nmol/L (14.2 ± 0.7 ng/mL; -2.50 nmol/L/month, P < 0.0001). PTH followed the opposite trend with baseline, repletion-end and post-repletion values being 144.2 ± 12.0, 109.6 ± 7.5 and 129.2 ± 11.4 ng/L, respectively. VitD repletion during the summer was associated with significantly higher at repletion-end 25(OH)D compared with any other time of year [summer 80.9 ± 4.0, autumn 64.1 ± 3.0 (P = 0.002), winter 48.9 ± 3.0 (P <0.001), spring 63.8 ± 2.5 nmol/L (P <0.001)]. There was no hypercalcaemia during repletion and renal transplant function remained stable without any evidence of allograft rejection. VitD repletion can safely and effectively be achieved in the majority of chronic stable RTRs using a 6-month bolus intermediate-dose schedule. Winter repletion is associated with an inadequate response in 25(OH)D; however, all patients experience a post-repletion fall towards deficiency in the absence of maintenance supplementation, irrespective of the season of repletion.
肾移植受者(RTRs)由于慢性肾病以及被要求避免日晒行为,常常维生素D(VitD)缺乏。补充VitD或许是必要的,但如何补充以及补充多久尚不清楚,季节性对补充成功与否的影响也不清楚。我们在一大群稳定的长期RTRs中研究了季节性对VitD补充后VitD状态的影响。分析了98例接受过VitD补充的RTRs的102个VitD补充疗程的血清25-羟维生素D [25(OH)D]浓度和骨生化参数。如果补充前血清VitD在20至50 nmol/L之间,则在6个月内给予240000 IU骨化三醇进行补充;如果VitD<20 nmol/L,则给予360000 IU。补充后12个月时,75例患者可获得25(OH)D和甲状旁腺激素(PTH)数据。基线时,25(OH)D为20.1±1.0 nmol/L,补充后升至65.4±1.8 nmol/L(每月增加7.55 nmol/L,P<0.0001)。补充后12个月且未再给予VitD后,25(OH)D降至35.4±1.8 nmol/L(14.2±0.7 ng/mL;每月下降2.50 nmol/L,P<0.0001)。PTH呈现相反趋势,基线、补充结束时和补充后的值分别为144.2±12.0、109.6±7.5和129.2±11.4 ng/L。与一年中的任何其他时间相比,夏季进行VitD补充时,补充结束时的25(OH)D显著更高[夏季80.9±4.0,秋季64.1±3.0(P=0.002),冬季48.9±3.0(P<0.001),春季63.8±2.5 nmol/L(P<0.001)]。补充过程中无高钙血症发生,肾移植功能保持稳定,无任何移植肾排斥反应的证据。使用6个月大剂量中间剂量方案,大多数慢性稳定的RTRs能够安全有效地实现VitD补充。冬季补充时25(OH)D反应不足;然而,无论补充季节如何,所有患者在无维持补充的情况下补充后都会出现向缺乏状态的下降。